Browsing Tag
metastatic pancreatic ductal adenocarcinoma
2 posts
Is elraglusib emerging as a new frontline option in metastatic PDAC?
Read how Actuate Therapeutics’ elraglusib Phase 2 survival data could reshape metastatic PDAC treatment and investor expectations.
Could repeated VCN-01 dosing overcome long-standing survival barriers in metastatic PDAC?
Theriva Biologics advances VCN-01 into phase 3 for metastatic pancreatic cancer with FDA and EMA guidance. Discover what this means for trial execution and survival outcomes.